VJHemOnc is committed to improving our service to you

ICML 2019 | Providing a PLATFORM: first results for liso-cel plus durvalumab in R/R B-cell NHL

VJHemOnc is committed to improving our service to you

Tanya Siddiqi

Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the first results of the PLATFORM trial (NCT03310619). She discusses the safety of lisocabtagene maraleucel given with durvalumab to patients with relapsed/refractory aggressive B-cell non-Hodgkin lympoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter